Joel Moake, MD

HemOnc Today recently convened its well-respected Section Editors to present on ‘hot’ or controversial topics they deemed important to their subspecialty area. Presented here is Joel Moake, MD’s, discussion of his hit list of topics that he believed fulfilled this qualification. HemOnc Today will continue to follow and expand coverage of these topics in the ensuing months. We hope you find these executive overviews informative.

In my update on thrombotic thrombocytopenia purpura published in [May 10 issue, page 4], I discussed new insights and possible new therapies for this most life-threatening form of thrombotic microangiopathy.

The pathophysiology of various types of thrombotic microangiopathies is coming progressively into focus and therapeutic advances are likely to follow at a rapid pace. The discussion below focuses on thrombotic thrombocytopenic purpura.